

YOUR INFUSION DIARY FOR **cipagluco**sidase **alfa** **home infusion**

Some people may have side-effects when taking this medicine. If you have any unwanted side-effects you should talk to your doctor, pharmacist or other healthcare professional. This includes any possible side-effects not listed in this leaflet. Also, you can help make sure medicines remain as safe as possible by reporting unwanted side-effects using the Yellow Card Scheme via www.mhra.gov.uk/yellowcard or by searching for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively, you can also report side-effects to Amicus Medical Information on: Tel: **08082346864**; or email: drugsafety@amicusrx.com.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

ADMINISTRATION DETAILS (TO BE COMPLETED BY TREATING PHYSICIAN)

Date of first administration	
First infusion at home	

CIPAGLUCOSIDASE ALFA/MIGLUSTAT DOSING REGIMEN

Miglustat dose	
Cipaglucoisidase alfa dose	
Frequency	
Rate of infusion	
Required reconstituted volume (mL)	
Total volume in infusion bag (mL)	
Pre-treatment medication (if applicable)	
Reasons for cipaglucoisidase alfa infusion at home	
Findings and actions from the initial interview	
Indicate support to be provided by infusion healthcare professional/ nurse at home	

NECESSARY ACTIONS IN THE EVENT OF A SEVERE INFUSION-ASSOCIATED REACTION OR HYPERSENSITIVITY REACTION

(TO BE COMPLETED BY TREATING PHYSICIAN)

1	STOP the infusion														
2	<table border="1" style="width: 100%;"> <tr> <td style="background-color: #e0f2f1;">Call the emergency services</td> <td></td> </tr> </table>	Call the emergency services													
Call the emergency services															
3	<table border="1" style="width: 100%;"> <tr> <td colspan="2" style="background-color: #e0f2f1;">Call your treating physician</td> </tr> <tr> <td style="width: 50%;">Telephone number</td> <td></td> </tr> <tr> <td>Telephone number (24hr)</td> <td></td> </tr> <tr> <td>Name of physician</td> <td></td> </tr> <tr> <td>Name of clinic</td> <td></td> </tr> <tr> <td>Total volume in infusion bag (mL)</td> <td></td> </tr> <tr> <td>Address</td> <td></td> </tr> </table>	Call your treating physician		Telephone number		Telephone number (24hr)		Name of physician		Name of clinic		Total volume in infusion bag (mL)		Address	
Call your treating physician															
Telephone number															
Telephone number (24hr)															
Name of physician															
Name of clinic															
Total volume in infusion bag (mL)															
Address															
4	<table border="1" style="width: 100%;"> <tr> <td colspan="2" style="background-color: #e0f2f1;">Emergency medication</td> </tr> <tr> <td style="width: 50%;">Medication, including dose</td> <td></td> </tr> </table>	Emergency medication		Medication, including dose											
Emergency medication															
Medication, including dose															
5	<table border="1" style="width: 100%;"> <tr> <td colspan="2" style="background-color: #e0f2f1;">Patient's contact person to be notified</td> </tr> <tr> <td style="width: 50%;">Name</td> <td></td> </tr> <tr> <td>Telephone</td> <td></td> </tr> </table>	Patient's contact person to be notified		Name		Telephone									
Patient's contact person to be notified															
Name															
Telephone															

COMPLETE THIS FORM FOR EVERY INFUSION SESSION

The patient and/or caregiver(s) have been informed about the associated risks of home infusion of cipaglucoisidase alfa, and proper education on the use of emergency medications has been provided. In the event of any infusion-associated reaction, the infusion must be immediately discontinued. Necessary actions in the event of a severe infusion-associated reaction, including emergency contact details, are described in this Infusion Diary. Keep this information readily available during the infusion procedure. To request additional copies of this infusion diary please email: info@amicusrx.co.uk or call: **01753 888 567**.

Date of first administration	
First infusion at home	
INFUSION SESSION	
Date of infusion	
Infusion healthcare professional/nurse	
Caregiver, if present	
DOSE	
Miglustat dose	
Time of miglustat dose	
Cipaglucoisidase alfa dose	
Patient weight (kg)	
Cipaglucoisidase alfa batch/lot number	
Time of cipaglucoisidase alfa infusion start	
Required reconstituted volume (mL)	
Number of vials used	
Duration of infusion	
Rate(s) of infusion	
Problems/Remarks related to the infusion, if any (including infusion-associated reaction(s), action taken, and outcome):	
Indicate support to be provided by infusion healthcare professional/nurse at home:	

COMPLETE THIS FORM FOR EVERY INFUSION SESSION

The patient and/or caregiver(s) have been informed about the associated risks of home infusion of cipaglucoSIDASE alfa, and proper education on the use of emergency medications has been provided. In the event of any infusion-associated reaction, the infusion must be immediately discontinued. Necessary actions in the event of a severe infusion-associated reaction, including emergency contact details, are described in this Infusion Diary. Keep this information readily available during the infusion procedure. To request additional copies of this infusion diary please email: info@amicusrx.co.uk or call: **01753 888 567**.

Date of first administration	
First infusion at home	

INFUSION SESSION	
Date of infusion	
Infusion healthcare professional/nurse	
Caregiver, if present	

DOSE	
Miglustat dose	
Time of miglustat dose	
CipaglucoSIDASE alfa dose	
Patient weight (kg)	
CipaglucoSIDASE alfa batch/lot number	
Time of cipaglucoSIDASE alfa infusion start	
Required reconstituted volume (mL)	
Number of vials used	
Duration of infusion	
Rate(s) of infusion	
Problems/Remarks related to the infusion, if any (including infusion-associated reaction(s), action taken, and outcome):	
Indicate support to be provided by infusion healthcare professional/nurse at home:	

COMPLETE THIS FORM FOR EVERY INFUSION SESSION

The patient and/or caregiver(s) have been informed about the associated risks of home infusion of cipaglucoSIDASE alfa, and proper education on the use of emergency medications has been provided. In the event of any infusion-associated reaction, the infusion must be immediately discontinued. Necessary actions in the event of a severe infusion-associated reaction, including emergency contact details, are described in this Infusion Diary. Keep this information readily available during the infusion procedure. To request additional copies of this infusion diary please email: info@amicusrx.co.uk or call: **01753 888 567**.

Date of first administration	
First infusion at home	

INFUSION SESSION	
Date of infusion	
Infusion healthcare professional/nurse	
Caregiver, if present	

DOSE	
Miglustat dose	
Time of miglustat dose	
CipaglucoSIDASE alfa dose	
Patient weight (kg)	
CipaglucoSIDASE alfa batch/lot number	
Time of cipaglucoSIDASE alfa infusion start	
Required reconstituted volume (mL)	
Number of vials used	
Duration of infusion	
Rate(s) of infusion	
Problems/Remarks related to the infusion, if any (including infusion-associated reaction(s), action taken, and outcome):	
Indicate support to be provided by infusion healthcare professional/nurse at home:	

COMPLETE THIS FORM FOR EVERY INFUSION SESSION

The patient and/or caregiver(s) have been informed about the associated risks of home infusion of cipaglucoSIDASE alfa, and proper education on the use of emergency medications has been provided. In the event of any infusion-associated reaction, the infusion must be immediately discontinued. Necessary actions in the event of a severe infusion-associated reaction, including emergency contact details, are described in this Infusion Diary. Keep this information readily available during the infusion procedure. To request additional copies of this infusion diary please email: info@amicusrx.co.uk or call: **01753 888 567**.

Date of first administration	
First infusion at home	

INFUSION SESSION	
Date of infusion	
Infusion healthcare professional/nurse	
Caregiver, if present	

DOSE	
Miglustat dose	
Time of miglustat dose	
CipaglucoSIDASE alfa dose	
Patient weight (kg)	
CipaglucoSIDASE alfa batch/lot number	
Time of cipaglucoSIDASE alfa infusion start	
Required reconstituted volume (mL)	
Number of vials used	
Duration of infusion	
Rate(s) of infusion	
Problems/Remarks related to the infusion, if any (including infusion-associated reaction(s), action taken, and outcome):	
Indicate support to be provided by infusion healthcare professional/nurse at home:	

COMPLETE THIS FORM FOR EVERY INFUSION SESSION

The patient and/or caregiver(s) have been informed about the associated risks of home infusion of cipaglucoSIDASE alfa, and proper education on the use of emergency medications has been provided. In the event of any infusion-associated reaction, the infusion must be immediately discontinued. Necessary actions in the event of a severe infusion-associated reaction, including emergency contact details, are described in this Infusion Diary. Keep this information readily available during the infusion procedure. To request additional copies of this infusion diary please email: info@amicusrx.co.uk or call: **01753 888 567**.

Date of first administration	
First infusion at home	

INFUSION SESSION	
Date of infusion	
Infusion healthcare professional/nurse	
Caregiver, if present	

DOSE	
Miglustat dose	
Time of miglustat dose	
CipaglucoSIDASE alfa dose	
Patient weight (kg)	
CipaglucoSIDASE alfa batch/lot number	
Time of cipaglucoSIDASE alfa infusion start	
Required reconstituted volume (mL)	
Number of vials used	
Duration of infusion	
Rate(s) of infusion	
Problems/Remarks related to the infusion, if any (including infusion-associated reaction(s), action taken, and outcome):	
Indicate support to be provided by infusion healthcare professional/nurse at home:	

COMPLETE THIS FORM FOR EVERY INFUSION SESSION

The patient and/or caregiver(s) have been informed about the associated risks of home infusion of cipaglucoSIDASE alfa, and proper education on the use of emergency medications has been provided. In the event of any infusion-associated reaction, the infusion must be immediately discontinued. Necessary actions in the event of a severe infusion-associated reaction, including emergency contact details, are described in this Infusion Diary. Keep this information readily available during the infusion procedure. To request additional copies of this infusion diary please email: info@amicusrx.co.uk or call: **01753 888 567**.

Date of first administration	
First infusion at home	

INFUSION SESSION	
Date of infusion	
Infusion healthcare professional/nurse	
Caregiver, if present	

DOSE	
Miglustat dose	
Time of miglustat dose	
CipaglucoSIDASE alfa dose	
Patient weight (kg)	
CipaglucoSIDASE alfa batch/lot number	
Time of cipaglucoSIDASE alfa infusion start	
Required reconstituted volume (mL)	
Number of vials used	
Duration of infusion	
Rate(s) of infusion	
Problems/Remarks related to the infusion, if any (including infusion-associated reaction(s), action taken, and outcome):	
Indicate support to be provided by infusion healthcare professional/nurse at home:	

COMPLETE THIS FORM FOR EVERY INFUSION SESSION

The patient and/or caregiver(s) have been informed about the associated risks of home infusion of cipaglucoSIDASE alfa, and proper education on the use of emergency medications has been provided. In the event of any infusion-associated reaction, the infusion must be immediately discontinued. Necessary actions in the event of a severe infusion-associated reaction, including emergency contact details, are described in this Infusion Diary. Keep this information readily available during the infusion procedure. To request additional copies of this infusion diary please email: info@amicusrx.co.uk or call: **01753 888 567**.

Date of first administration	
First infusion at home	

INFUSION SESSION	
Date of infusion	
Infusion healthcare professional/nurse	
Caregiver, if present	

DOSE	
Miglustat dose	
Time of miglustat dose	
CipaglucoSIDASE alfa dose	
Patient weight (kg)	
CipaglucoSIDASE alfa batch/lot number	
Time of cipaglucoSIDASE alfa infusion start	
Required reconstituted volume (mL)	
Number of vials used	
Duration of infusion	
Rate(s) of infusion	
Problems/Remarks related to the infusion, if any (including infusion-associated reaction(s), action taken, and outcome):	
Indicate support to be provided by infusion healthcare professional/nurse at home:	

COMPLETE THIS FORM FOR EVERY INFUSION SESSION

The patient and/or caregiver(s) have been informed about the associated risks of home infusion of cipaglucoSIDASE alfa, and proper education on the use of emergency medications has been provided. In the event of any infusion-associated reaction, the infusion must be immediately discontinued. Necessary actions in the event of a severe infusion-associated reaction, including emergency contact details, are described in this Infusion Diary. Keep this information readily available during the infusion procedure. To request additional copies of this infusion diary please email: info@amicusrx.co.uk or call: **01753 888 567**.

Date of first administration	
First infusion at home	

INFUSION SESSION	
Date of infusion	
Infusion healthcare professional/nurse	
Caregiver, if present	

DOSE	
Miglustat dose	
Time of miglustat dose	
CipaglucoSIDASE alfa dose	
Patient weight (kg)	
CipaglucoSIDASE alfa batch/lot number	
Time of cipaglucoSIDASE alfa infusion start	
Required reconstituted volume (mL)	
Number of vials used	
Duration of infusion	
Rate(s) of infusion	
Problems/Remarks related to the infusion, if any (including infusion-associated reaction(s), action taken, and outcome):	
Indicate support to be provided by infusion healthcare professional/nurse at home:	

COMPLETE THIS FORM FOR EVERY INFUSION SESSION

The patient and/or caregiver(s) have been informed about the associated risks of home infusion of cipaglucoSIDASE alfa, and proper education on the use of emergency medications has been provided. In the event of any infusion-associated reaction, the infusion must be immediately discontinued. Necessary actions in the event of a severe infusion-associated reaction, including emergency contact details, are described in this Infusion Diary. Keep this information readily available during the infusion procedure. To request additional copies of this infusion diary please email: info@amicusrx.co.uk or call: **01753 888 567**.

Date of first administration	
First infusion at home	

INFUSION SESSION	
Date of infusion	
Infusion healthcare professional/nurse	
Caregiver, if present	

DOSE	
Miglustat dose	
Time of miglustat dose	
CipaglucoSIDASE alfa dose	
Patient weight (kg)	
CipaglucoSIDASE alfa batch/lot number	
Time of cipaglucoSIDASE alfa infusion start	
Required reconstituted volume (mL)	
Number of vials used	
Duration of infusion	
Rate(s) of infusion	
Problems/Remarks related to the infusion, if any (including infusion-associated reaction(s), action taken, and outcome):	
Indicate support to be provided by infusion healthcare professional/nurse at home:	

COMPLETE THIS FORM FOR EVERY INFUSION SESSION

The patient and/or caregiver(s) have been informed about the associated risks of home infusion of cipaglucoisidase alfa, and proper education on the use of emergency medications has been provided. In the event of any infusion-associated reaction, the infusion must be immediately discontinued. Necessary actions in the event of a severe infusion-associated reaction, including emergency contact details, are described in this Infusion Diary. Keep this information readily available during the infusion procedure. To request additional copies of this infusion diary please email: info@amicusrx.co.uk or call: **01753 888 567**.

Date of first administration	
First infusion at home	
INFUSION SESSION	
Date of infusion	
Infusion healthcare professional/nurse	
Caregiver, if present	
DOSE	
Miglustat dose	
Time of miglustat dose	
Cipaglucoisidase alfa dose	
Patient weight (kg)	
Cipaglucoisidase alfa batch/lot number	
Time of cipaglucoisidase alfa infusion start	
Required reconstituted volume (mL)	
Number of vials used	
Duration of infusion	
Rate(s) of infusion	
Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome):	
Indicate support to be provided by infusion healthcare professional/nurse at home:	

